Editas Medicine (EDIT) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wells Fargo | Upgraded | Equal-Weight → Overweight | $6.00 from $4.00 | Oct 8, 2026 |
| Guggenheim | Upgraded | Neutral → Buy | $5.00 | Sep 23, 2026 |
| Ladenburg Thalmann | Initiated Coverage | Buy | $6.00 | Aug 18, 2026 |
| Chardan Capital | Maintained | Buy | $4.00 from $3.50 | May 5, 2026 |
| Jones Trading | Upgraded | Hold → Buy | $8.00 | Mar 10, 2026 |
| Chardan Capital | Maintained | Buy | $3.50 | Mar 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 | Sep 5, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $4.00 from $3.00 | Sep 3, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 from $3.00 | Aug 15, 2025 |
| Baird | Maintained | Outperform | $6.00 from $4.00 | Aug 13, 2025 |
| Baird | Maintained | Outperform | $4.00 from $8.00 | May 13, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $3.00 | Apr 28, 2025 |
| JP Morgan | Downgraded | Neutral → Underweight | — | Dec 16, 2024 |
| Evercore ISI Group | Maintained | Outperform | $5.00 from $7.00 | Dec 16, 2024 |
| Stifel | Downgraded | Buy → Hold | $3.00 from $11.00 | Dec 13, 2024 |
| Baird | Maintained | Outperform | $8.00 from $10.00 | Dec 13, 2024 |
| Chardan Capital | Downgraded | Buy → Neutral | — | Dec 13, 2024 |
| Barclays | Maintained | Equal-Weight | $3.00 from $5.00 | Dec 13, 2024 |
| RBC Capital | Maintained | Sector Perform | $4.00 from $5.00 | Dec 13, 2024 |
| Wells Fargo | Downgraded | Overweight → Equal-Weight | $4.00 from $7.00 | Dec 11, 2024 |
Frequently asked questions
What is the price target for EDIT stock?
The average 12-month analyst price target for Editas Medicine (EDIT) is $5.67, with a high estimate of $6.00 and a low of $5.00, across 3 analysts.
Is EDIT a buy, sell, or hold?
Analysts covering Editas Medicine currently average a Buy rating: 8 buy, 2 hold and 2 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for EDIT?
The average price target of $5.67 implies 106.06% upside from the last price of $2.75.
What is the latest analyst rating on EDIT?
On Oct 8, 2026, Wells Fargo upgraded Editas Medicine to Overweight with a price target of $6.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.